For TSHA120 in GAN our new comprehensive data analysis utilizing the Disease Progression Model DPM was submitted to the FDA and we plan to review the potential regulatory pathway for TSHA120 with the Agency expected in the third quarter Mr Nolan continued Our successful completion of a 150 million PIPE from toptier investors significantly bolsters our balance sheet and we believe highlights the enthusiasm for our TSHA102 program and the early clinical readout of the first patient treated in the REVEAL trial